{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:18:55Z","timestamp":1769509135657,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015631","name":"Merck Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.anai.2018.02.003","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T13:08:31Z","timestamp":1518181711000},"page":"495-503.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen\u2013induced allergic rhinoconjunctivitis in an environmental exposure unit"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0725-2353","authenticated-orcid":false,"given":"Anne K.","family":"Ellis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark W.","family":"Tenn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Steacy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew G.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Nolte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2018.02.003_bib0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-8-7","article-title":"The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients","volume":"8","author":"Keith","year":"2012","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0015","article-title":"Allergic rhinitis (AR) is now estimated to affect some 1.4 billion people globally and continues to be on the rise [editorial]","volume":"26","author":"Schwindt","year":"2012","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.anai.2018.02.003_bib0020","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2500\/ajra.2013.27.3965","article-title":"Allergic rhinoconjunctivitis in the Australian population: burden of disease and attitudes to intranasal corticosteroid treatment","volume":"27","author":"Katelaris","year":"2013","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.anai.2018.02.003_bib0025","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jaci.2015.04.047","article-title":"International consensus on allergy immunotherapy","volume":"136","author":"Jutel","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0030","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaci.2010.11.034","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents","volume":"127","author":"Blaiss","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2010.11.035","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults","volume":"127","author":"Nelson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0040","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.anai.2013.11.018","article-title":"Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial","volume":"112","author":"Maloney","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.anai.2013.07.019","article-title":"Environmental exposure unit: a sensitive, specific, and reproducible methodology for allergen challenge","volume":"111","author":"Ellis","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11882-015-0514-4","article-title":"Controlled allergen challenge facilities and their unique contributions to allergic rhinitis research","volume":"15","author":"North","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.anai.2018.02.003_bib0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1710-1492-9-16","article-title":"A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis","volume":"9","author":"Ellis","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.anai.2016.07.018","article-title":"Efficacy of the novel nasal steroid S0597 tested in an environmental exposure unit","volume":"117","author":"Ellis","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0065","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaci.2016.11.043","article-title":"Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis","volume":"140","author":"Ellis","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000330649","article-title":"Immunotherapy is allergen-specific: a double-blind trial of mite or timothy extract in mite and grass dual-allergic patients","volume":"158","author":"Dreborg","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0075","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/0091-6749(78)90116-1","article-title":"The clinical and immunologic specificity of immunotherapy","volume":"61","author":"Norman","year":"1978","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0080","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1034\/j.1398-9995.2000.00368.x","article-title":"Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis, II: side-effects","volume":"55","author":"Winther","year":"2000","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2018.02.003_bib0085","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13223-015-0071-3","article-title":"Clinical validation of controlled grass pollen challenge in the Environmental Exposure Unit (EEU)","volume":"11","author":"Ellis","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0095","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaci.2009.06.006","article-title":"Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber","volume":"124","author":"Horak","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0100","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.jaci.2014.12.1911","article-title":"Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber","volume":"135","author":"Nolte","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jaci.2013.05.032","article-title":"Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen","volume":"133","author":"Patel","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0110","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaci.2012.01.077","article-title":"A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis","volume":"129","author":"Carr","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.02.003_bib0115","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.anai.2011.07.014","article-title":"Nasal carbon dioxide for the symptomatic treatment of perennial allergic rhinitis","volume":"107","author":"Casale","year":"2011","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618301121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618301121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:18:53Z","timestamp":1761052733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120618301121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1081120618301121"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2018.02.003","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen\u2013induced allergic rhinoconjunctivitis in an environmental exposure unit","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2018.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}